Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RegenoGel-SP
- Development stage
- Unknown
- Lead developer
- ProCore
- Administration
- Intraarticular
01
Overview
**RegenoGel-SP** is an investigational autologous intra-articular viscoelastic gel developed by ProCore for moderate-to-severe knee osteoarthritis. It is prepared from the patient's plasma fibrinogen chemically linked to high-molecular-weight hyaluronic acid, forming a stable fibrinogen-hyaluronic acid matrix intended to provide joint viscosupplementation, load dissipation, shock absorption, and a local microenvironment supportive of cartilage repair. RegenoGel-SP was evaluated against hyaluronic acid in the registered Phase 1 randomized, open-label, active-controlled study NCT02188771. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02188771))
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on RegenoGel-SP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RegenoGel-SP.